R&D channel feed

In an­oth­er shock­er, FDA re­jects Bio­Marin’s he­mo­phil­ia A gene ther­a­py, de­mand­ing more da­ta on dura­bil­i­ty

5 years ago
FDA+

An­oth­er blow to NASH, dis­ap­point­ing tri­al re­sults spell end for dark­horse play­er Al­bireo

5 years ago

FDA hands Gilead a stun­ning re­jec­tion for block­buster RA can­di­date fil­go­tinib, deal­ing CEO O’Day a ma­jor set­back

5 years ago
FDA+

My­lan wins ear­ly FDA OK of a Tec­fidera knock­off, and they're launch­ing with an eye to top­pling Bio­gen's block­buster fran­chise

5 years ago
FDA+

An MD An­der­son study points to an­oth­er use for No­var­tis’ GSK-born can­cer drugs

5 years ago

Eli Lil­ly is bet­ting $1B-plus that it can make yet an­oth­er PD-1 drug a hit in the US. How about a deep dis­count this time?

5 years ago

As­traZeneca is chang­ing up dos­ing reg­i­mens of its check­point play­er in the face of the pan­dem­ic. The FDA ap­pears ready to make a quick as­sist

5 years ago
FDA+

Mer­ck pre­pares to fi­nal­ly break ground on $1.3B Lon­don re­search hub

5 years ago
Pharma

New­ly ar­rived on Nas­daq, Po­sei­da qui­et­ly sig­nals a clin­i­cal hold trig­gered by a pa­tient death in PhI — shares crater

5 years ago
FDA+

Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

5 years ago
FDA+

Black­stone fi­nal­izes R&D pact with Al­ny­lam as part of ear­li­er $2 bil­lion in­vest­ment

5 years ago
Deals

In blow to an­ti-ag­ing field, Uni­ty Biotech­nol­o­gy fails first ma­jor study, cuts lead pro­gram

5 years ago

FDA ap­proves the third NMOSD drug in 18 months as Roche/Genen­tech beefs up its port­fo­lio of drugs for neu­ro­log­i­cal dis­or­ders

5 years ago
FDA+

US gov­ern­ment re­port­ed­ly be­gins prepar­ing for Covid-19 chal­lenge tri­als. Are they eth­i­cal?

5 years ago
Coronavirus

Eye­ing in-vi­vo edit­ing, Mam­moth li­cens­es Jen­nifer Doud­na’s new CRISPR en­zyme

5 years ago
Deals

Cal­lid­i­tas bets up to $102M on a biotech buy­out, snag­ging a once-failed PBC drug

5 years ago
Deals

FDA puts up a red light for Pas­sage Bio’s first gene ther­a­py pro­gram, de­lay­ing a pro­gram from James Wilson's group at Penn

5 years ago
FDA+

How much has pre­ci­sion med­i­cine helped? A new NCI study of­fers clues but pro­vokes skep­tics

5 years ago

No­vo Nordisk gets PhI­II he­mo­phil­ia tri­als for a Roche ri­val back on track af­ter com­plet­ing work-around on blood clot threat

5 years ago

Ful­crum stum­bles in PhII of old GSK drug, send­ing shares tum­bling

5 years ago

Lig­and scoops up Pfenex for up to $516M, adding pro­teins to their an­ti­body chick­ens and de­liv­ery tech

5 years ago
Deals

Fir­dapse fails PhI­II for myas­the­nia gravis as Cat­a­lyst keeps look­ing for ex­pand­ed la­bel

5 years ago

In­novent and Eli Lil­ly chal­lenge Mer­ck­'s mega-block­buster Keytru­da in non-small cell lung can­cer field

5 years ago

Anap­tys­Bio's etokimab pro­vides more dis­ap­point­ing re­sults, rais­ing ques­tions about com­pound's fu­ture

5 years ago
First page Previous page 192193194195196197198 Next page Last page
A service from the Financial Times